Abstract: ObjectiveTo assess whether targeted agents added to gemcitabine has benefit for advanced pancreatic cancer. MethodsBy searching CNKI， PubMed， Cochrane Library and EMBASE databases， data were retrieved from phase Ⅲ clinical randomized controlled trials to compare the efficacy and safety  between targeted therapy plus gemcitabine and gemcitabine alone for advanced pancreatic cancer. The primary endpoints included overall survival (OS)， progressionfree survival (PFS)， objective response rate (ORR)， clinical benefit rate (CBR)， and toxicity rate. ResultsThirteen randomized controlled trials involving a total of 6 664 patients were selected for metaanalysis. In the pooled analysis， no statistical difference was found on OS (HR=0.984，95%CI=0.9301.041，P=0.567)， PFS   (HR=0.955，95%CI=0.8981.015，P=0.137) and ORR (OR=1.188，95%CI=0.9781.442，P=0.082) for targeted agents plus gemcitabine compared with gemcitabine alone.  Targeted agents demonstrated a significant increase on CBR  (OR=1.249，95%CI=1.0391.501，P=0.018). The side reactions of medicine， such as grade 34 neutropenia， diarrhoea and rash were significantly increased in targeted agents. ConclusionBased on the outcomes of this analysis， addition of targeted agents can not improve OS and PFS of patients.

Key words: pancreatic neoplasms, immunotoxins, antineoplastic combined chomotherapy protocols, metaanalysis